These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37547956)

  • 41. Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.
    Wei T; Song J; Liang K; Li L; Mo X; Huang Z; Chen G; Mao N; Yang J
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1049-1064. PubMed ID: 33387038
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protective Effects of MicroRNA-126 on Human Cardiac Microvascular Endothelial Cells Against Hypoxia/Reoxygenation-Induced Injury and Inflammatory Response by Activating PI3K/Akt/eNOS Signaling Pathway.
    Yang HH; Chen Y; Gao CY; Cui ZT; Yao JM
    Cell Physiol Biochem; 2017; 42(2):506-518. PubMed ID: 28578351
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oncogenic role of abnormal spindle‑like microcephaly‑associated protein in lung adenocarcinoma.
    Wang J; Liang J; Li H; Han J; Jiang J; Li Y; Feng Z; Zhao R; Tian H
    Int J Oncol; 2021 May; 58(5):. PubMed ID: 33786609
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
    Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
    J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Integrated bulk and single-cell RNA sequencing identifies an aneuploidy-based gene signature to predict sensitivity of lung adenocarcinoma to traditional chemotherapy drugs and patients' prognosis.
    Wang X; Chen J; Li C; Liu Y; Chen S; Lv F; Lan K; He W; Zhu H; Xu L; Ma K; Guo H
    PeerJ; 2024; 12():e17545. PubMed ID: 38938612
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CircPRKCI regulates proliferation, migration and cycle of lung adenocarcinoma cells by targeting miR-219a-5p-regulated CAMK1D.
    Sui MH; Zhang WW; Geng DM; Sun DJ
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1899-1909. PubMed ID: 33660800
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
    Sun D; Qian H; Wang J; Xie T; Teng F; Li J; Xing P
    Cell Commun Signal; 2022 Oct; 20(1):156. PubMed ID: 36229854
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Landscape and dynamics of single tumor and immune cells in early and advanced-stage lung adenocarcinoma.
    Chen Z; Huang Y; Hu Z; Zhao M; Li M; Bi G; Zheng Y; Liang J; Lu T; Jiang W; Xu S; Zhan C; Xi J; Wang Q; Tan L
    Clin Transl Med; 2021 Mar; 11(3):e350. PubMed ID: 33783985
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PDGFBB facilitates tumorigenesis and malignancy of lung adenocarcinoma associated with PI3K-AKT/MAPK signaling.
    Xiu-Ying H; Yue-Xiang Z; Hui-Si Y; Hong-Zhou Y; Qing-Jie X; Ting-Hua W
    Sci Rep; 2024 Feb; 14(1):4191. PubMed ID: 38378786
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heterogeneity of tumor immune microenvironment in malignant and metastatic change in LUAD is revealed by single-cell RNA sequencing.
    Wang H; Han G; Chen J
    Aging (Albany NY); 2023 Jun; 15(12):5339-5354. PubMed ID: 37335089
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LncRNA TP73-AS1 promoted the progression of lung adenocarcinoma via PI3K/AKT pathway.
    Liu C; Ren L; Deng J; Wang S
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30541897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. scRNA-seq revealed high stemness epithelial malignant cell clusters and prognostic models of lung adenocarcinoma.
    Lin G; Gao Z; Wu S; Zheng J; Guo X; Zheng X; Chen R
    Sci Rep; 2024 Feb; 14(1):3709. PubMed ID: 38355636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.
    Chen Y; Tang J; Lu T; Liu F
    Thorac Cancer; 2020 Jul; 11(7):1848-1860. PubMed ID: 32395869
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transcriptomic landscape of endothelial cells: Key tumor microenvironment components indicating variable clinical outcomes in pancreatic ductal adenocarcinoma.
    Xie P; Tan SY; Li HF; Tang HD; Zhou JH
    Environ Toxicol; 2024 Feb; 39(2):572-582. PubMed ID: 37449672
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CLDN18.1 attenuates malignancy and related signaling pathways of lung adenocarcinoma in vivo and in vitro.
    Luo J; Chimge NO; Zhou B; Flodby P; Castaldi A; Firth AL; Liu Y; Wang H; Yang C; Marconett CN; Crandall ED; Offringa IA; Frenkel B; Borok Z
    Int J Cancer; 2018 Dec; 143(12):3169-3180. PubMed ID: 30325015
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MiR-7 regulates the PI3K/AKT/VEGF pathway of retinal capillary endothelial cell and retinal pericytes in diabetic rat model through IRS-1 and inhibits cell proliferation.
    Cao YL; Liu DJ; Zhang HG
    Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4427-4430. PubMed ID: 30058674
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DNA repair/recombination protein 54L promotes the progression of lung adenocarcinoma by activating mTORC1 pathway.
    Liu C; Ren W; Zhang Z; Guan J
    Hum Cell; 2023 Jan; 36(1):421-433. PubMed ID: 36454390
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MTHFD2 promotes tumorigenesis and metastasis in lung adenocarcinoma by regulating AKT/GSK-3β/β-catenin signalling.
    Shi Y; Xu Y; Yao J; Yan C; Su H; Zhang X; Chen E; Ying K
    J Cell Mol Med; 2021 Jul; 25(14):7013-7027. PubMed ID: 34121323
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
    Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
    J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. METTL3-mediated m
    Zhou YF; Li JT; Zheng QL; Ren KL; Yi CC
    Kaohsiung J Med Sci; 2024 Feb; 40(2):150-160. PubMed ID: 38088510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.